Novo Nordisk A/S (NVO)
| Market Cap | 324.15B |
| Revenue (ttm) | 43.92B |
| Net Income (ttm) | 15.16B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.40 |
| PE Ratio | 21.99 |
| Forward PE | 17.78 |
| Dividend | $1.61 (2.16%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 5,887,517 |
| Open | 74.15 |
| Previous Close | 72.65 |
| Day's Range | 73.97 - 75.16 |
| 52-Week Range | 57.00 - 148.15 |
| Beta | 0.22 |
| Analysts | Strong Buy |
| Price Target | 128.00 (+71.12%) |
| Earnings Date | May 7, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $128.0, which is an increase of 71.12% from the latest price.
News
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track.
Novo Nordisk's Buy Scenario Is Supported By Quantitative Evidence
Novo Nordisk's sharp 54% decline is driven by LLY's competition, regulatory issues, and leadership change, but its fundamentals remain robust. Despite recent setbacks, NVO continues to deliver strong ...
Final Trade: ASML, XYZ, XLC, NVO
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Weight-loss drugs like Ozempic and Wegovy continue to be in high demand—and expensive. Are prices likely to come down soon?
The supply of GLP-1 drugs has been increasing, but they're still expensive for most patients. Here are answers to some questions consumers have.
Is Novo Nordisk Immune To President Trump's Drug Price Plans
Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks. I believe this is due to the strong performance of its GLP-1 products and ...
Should everyone be taking drugs like Ozempic? Drugs in the GLP-1-category show promise for a growing list of health conditions
GLP-1 drugs for weight loss and treating diabetes show promise for an ever-expanding list of diseases.
Final Trade: AAPL, NVO, TLT, X
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Mizuho's Jared Holz talks what is next for Novo Nordisk
Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles.
Novo Nordisk's High Risk/Reward Proposition: 129% Rally Or 65% Drop?
Novo Nordisk A/S (NOVO-B) has entered the 18th and final phase of its long-term Weekly Adhishthana Cycle, marking a potentially transformative period. While the weekly charts point to a possible Nirva...
Novo Nordisk offers Wegovy for $199 for first month to new cash-paying customers
Novo Nordisk said on Thursday it is offering self-paying patients who are new to its weight loss drug Wegovy their first month of medicine for $199 through June 30.
New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptions New, one-time $199 first-m...
Focus: Novo Nordisk's former chief makes comeback to steer choice of new CEO
Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing yet."
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna's Evernorth unit said a new coverage deal with Eli Lilly and Novo Nordisk will bring lower copays for insured patients The company hopes the new discount, which caps monthly out-of-pocket costs ...
Novo Nordisk Foundation pledges $57 million to WHO amid US funding gap
The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to expand its tie-up with the United Nations agency for another four years, the ph...
Forget About Dividend Yield, Do This Instead
Focus on dividend sustainability and business quality, not just high yield, to build reliable passive income. Avoid overexposure to cyclical sectors; prioritize companies with resilient dividends thro...
Novo Nordisk Woes Weigh on Denmark's Economy. Here's How.
Denmark's economy contracted 0.5% in the first quarter of 2025, largely due to the pharmaceutical industry.
If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition)
I've added Novo Nordisk and Novartis to boost The Dividend Income Accelerator's healthcare allocation and global diversification, reducing overall risk and volatility. Both companies are attractively ...
Final Trade: NVO, TJX, XOM & DG
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker last week abruptly announced that longtime CEO Lars Fruergaard Jor...
Novo Nordisk announces CEO transition as share price slips
Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs.
35 Barron's Pro-Picks: One Ideal May DiviDog
Barron's interviewed eleven financial industry Roundtable-pros who tapped 65 predictions. Six non-ADR foreign-stocks and four mutual funds were dropped by YCharts screens of active US listings, leavin...
Final Trade: MSTY, NVO, DKS, HD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Novo Nordisk should be thinking about 'what's next,' says Dr. Kavita Patel
NBC News and MSNBC medical contributor Dr. Kavita Patel joins ‘Fast Money' to discuss Novo Nordisk after the company ousted its CEO on Friday, the competition among obesity drug makers, and more.
Novo Nordisk's CEO Ousted: Deep-Value Opportunity With Sentiment Risks
Novo Nordisk A/S' CEO exit raises governance questions, but continuity through internal succession likely limits strategic disruption. Valuation reset (~16.5x forward non-GAAP P/E) vs. LLY (~30x) crea...
Novo Nordisk should look to the US for its next CEO, analysts say
As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market...